Literature DB >> 11313399

Neonatal exposure to antigen induces a defective CD40 ligand expression that undermines both IL-12 production by APC and IL-2 receptor up-regulation on splenic T cells and perpetuates IFN-gamma-dependent T cell anergy.

B Min1, K L Legge, J J Bell, R K Gregg, L Li, J C Caprio, H Zaghouani.   

Abstract

T cell deletion and/or inactivation were considered the leading mechanisms for neonatal tolerance. However, recent investigations have indicated that immunity develops at the neonatal stage but evolves to guide later T cell responses to display defective and/or biased effector functions. Although neonatal-induced T cell modulation provides a useful approach to suppress autoimmunity, the mechanism underlying the biased function of the T cells remains unclear. In prior studies, we found that exposure of newborn mice to Ig-PLP1, a chimera expressing the encephalitogenic proteolipid protein (PLP) sequence 139-151, induced deviated Th2 lymph node cells producing IL-4 instead of IL-2 and anergic splenic T cells that failed to proliferate or produce IFN-gamma yet secreted significant amounts of IL-2. However, if assisted with IFN-gamma or IL-12, these anergic splenic T cells regained full responsiveness. The consequence of such biased/defective T cells responses was protection of the mice against experimental allergic encephalomyelitis. In this study, investigations were performed to delineate the mechanism underlying the novel form of IFN-gamma-dependent splenic anergy. Our findings indicate that CD40 ligand expression on these splenic T cells is defective, leading to noneffective cooperation between T lymphocytes and APCs and a lack of IL-12 production. More striking, this cellular system revealed a requirement for IL-2R expression for CD40 ligand-initiated, IL-12-driven progression of T cells into IFN-gamma production.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313399     DOI: 10.4049/jimmunol.166.9.5594

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Effect of in vivo administration of anti-CTLA-4 monoclonal antibody and IL-12 on the induction of low-dose oral tolerance.

Authors:  K S Barone; B Herms; L Karlosky; S Murray; J Qualls
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

2.  Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system.

Authors:  Jonathan Kipnis; Tal Mizrahi; Ehud Hauben; Iftach Shaked; Ethan Shevach; Michal Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-12       Impact factor: 11.205

3.  Murine neonates develop vigorous in vivo cytotoxic and Th1/Th2 responses upon exposure to low doses of NIMA-like alloantigens.

Authors:  Shannon J Opiela; Robert B Levy; Becky Adkins
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

4.  Adjuvanting an inactivated influenza vaccine with conjugated R848 improves the level of antibody present at 6months in a nonhuman primate neonate model.

Authors:  Beth C Holbrook; Ralph B D'Agostino; S Tyler Aycock; Matthew J Jorgensen; Mallinath B Hadimani; S Bruce King; Martha A Alexander-Miller
Journal:  Vaccine       Date:  2017-09-28       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.